查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924743

SPECT 和 PET 放射性藥物市場按模式、放射性藥物類型、適應症、最終用戶和分銷管道分類——2026 年至 2032 年全球預測

SPECT & PET Radiopharmaceuticals Market by Modality, Radiopharmaceutical Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

SPECT 和 PET 放射性藥物市場預計到 2025 年價值為 74.8 億美元，到 2026 年將成長至 81.8 億美元，複合年成長率為 10.28%，到 2032 年達到 148.5 億美元。

關鍵市場統計數據
基準年 2025 74.8億美元
預計年份：2026年 81.8億美元
預測年份 2032 148.5億美元
複合年成長率 (%) 10.28%

對SPECT和PET放射性藥物、其臨床作用以及在診斷和治療途徑中的策略意義進行簡明扼要的基本概述

本執行摘要首先清楚闡述了SPECT和PET放射性藥物作為現代診斷和治療流程中不可或缺的工具。引言部分將這些藥物置於分子生物學、成像物理學和臨床決策的交叉領域，重點強調了它們在心臟病學、神經病學和腫瘤學領域實現精準診斷、治療計劃制定和療效評估的作用。重點在於示蹤劑化學和影像技術如何共同促進患者分層和個人化治療方案的製定，從而影響從門診診斷中心到三級甲等大學醫院的臨床工作流程。

新的科學突破、供應鏈創新和監管變革如何重塑醫療保健領域的 SPECT 和 PET 放射性藥物格局

隨著科學、監管和營運方面的變革共同加速創新和應用，SPECT和PET放射性藥物的格局正在重塑。放射化學和迴旋加速器技術的進步擴大了可用同位素的選擇範圍，提高了診斷靈敏度，並促進了疾病特異性示踪劑的開發，從而提供可操作的生物學資訊。同時，檢測器技術和影像重建軟體的改進正在縮小不同成像方式在特定適應症方面的表現差距，促使人們重新思考臨床演算法和投資重點。

對2025年美國關稅調整對SPECT和PET放射性藥物的採購、製造和全球分銷的影響全面評估

美國宣布的2025年關稅調整方案為放射性藥物價值鏈帶來了新的限制和策略考量。進口關稅的變化不僅影響成品放射性藥物，還會影響關鍵的上游工程投入，例如前驅化學品、發生器零件和特殊包裝。這些調整迫使採購團隊和製造商重新評估供應商選擇、庫存管理政策和服務交付成本模式，以確保業務連續性並遵守採購和報銷框架。

針對細分市場的情報揭示了治療方式、放射性藥物化學、臨床適應症、終端用戶趨勢以及分銷管道對相關人員的影響。

對市場進行觀點，有助於將科學見解轉化為營運和商業決策。我們基於影像方式的市場分析區分了PET和SPECT。這種區分至關重要，因為影像方式的選擇會影響示蹤劑化學偏好、資本投資和臨床路徑設計。以PET為中心的流程往往側重於迴旋加速器或發生器耦合的同位素，並且由於其半衰期短，需要更嚴格的排程；而SPECT流程則可以利用更廣泛使用的Technetium試劑盒和成熟的分銷模式。

解讀區域趨勢，了解美洲、歐洲、中東和非洲以及亞太地區對科技採納、供應鏈韌性和政策環境的影響

區域趨勢對放射性藥物產業的技術應用、供應鏈設計和監管方式有顯著影響。在美洲，大型醫療中心先進的臨床應用、放射化學基礎設施領域不斷成長的私人投資，以及兼顧創新與病人安全的監管重點，共同塑造了該領域的生態系統。這些因素推動了在既定的學術-商業夥伴關係框架下進行複雜的PET示踪劑研發，同時也促使人們更加關注物流最佳化，以確保示踪劑在廣闊地域範圍內的及時供應。

在核子醫學領域，推動放射性藥物創新、策略聯盟、商業性化規模化與價值鏈整合的公司，其競爭與合作概況

放射性藥物領域的公司之間的差異體現在其示踪劑發現、同位素來源、生產規模化和分銷網路等各個環節的整合能力上。一些公司專注於先進的放射化學平台和產品線多元化，從而推動新型配體快速進入臨床試驗；而另一些公司則專注於放射性藥物和物流方面的卓越運營，透過完善的低溫運輸解決方案和區域分銷中心，確保短壽命同位素的穩定準時交付。

為產業領導者提供切實可行的策略建議，以加速產品開發、確保供應鏈的韌性並最佳化臨床路徑。

產業領導者應優先採取三項相輔相成的策略行動，以增強自身競爭優勢並確保放射性藥物的穩定供應。首先，投資建構靈活的生產和採購架構，將本地生產能力與檢驗的關鍵前驅物和包裝材料替代供應商結合。這種雙管齊下的方法既能快速擴大產能以滿足臨床需求高峰，又能降低因單一供應商中斷和關稅而導致的成本波動風險。

嚴謹的調查方法，描述了所呈現的研究結果的資料來源、專家檢驗、分析架構和品質保證通訊協定。

本研究採用混合方法，整合了定性專家訪談、與關鍵相關人員的諮詢以及對同行評審文獻和監管指南的系統性回顧。研究邀請了包括臨床研究人員、放射性藥物管理人員、監管專家和供應鏈負責人在內的行業專家，檢驗主題研究結果並提取公開文件中不常體現的營運洞察。這種綜合分析強調多方觀點的三角驗證，以減少偏見，並確保建議既體現科學有效性又體現商業性可行性。

最終綜合分析，提煉出放射性藥物領域的戰略意義、持續挑戰、投資和臨床整合機會

最終的綜合分析為放射性藥物生態系統中的相關人員提出了策略性建議，並重點闡述了當前面臨的挑戰和可採取的行動。目前面臨的挑戰包括短壽命同位素供應鏈的脆弱性、不同地區法規環境和報銷環境的差異，以及需要更有力的真實世界證據來支持早期應用中心以外的臨床推廣。應對這些挑戰需要各方共同努力，加強能力建構、進行監管對話，並進行有針對性的臨床檢驗，以證明其對病人有切實的益處。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. SPECT 和 PET 放射性藥物市場依影像方式分類

  • PET
  • SPECT

9. SPECT 和 PET 放射性藥物市場（按放射性藥物類型分類）

  • 氟18
    • FDG
    • 非FDG
  • 鎵-68
  • 銦111
  • 碘-123
  • Technetium-99M
    • 冷療包
    • 即用型

10. SPECT 和 PET 放射性藥物市場（依適應症分類）

  • 心臟病學
  • 神經病學
  • 腫瘤學

11. SPECT 和 PET 放射性藥物市場（按最終用戶分類）

  • 學術研究機構
  • 診斷中心
  • 醫院

12. SPECT 和 PET 放射性藥物市場按分銷管道分類

  • 離線
  • 線上

13. SPECT 和 PET 放射性藥物市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. SPECT 和 PET 放射性藥物市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國 SPECT 與 PET 放射性藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國SPECT與PET放射性藥物市場

第17章 中國SPECT與PET放射性藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Accelerator Applications
  • Bayer AG
  • Bracco Imaging SpA
  • Cardinal Health, Inc.
  • Curium Pharma
  • Eckert & Ziegler
  • GE Healthcare
  • IBA Molecular
  • Isotopia Molecular Imaging Ltd.
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • Life Molecular Imaging GmbH
  • Mallinckrodt plc
  • Nihon Medi-Physics Co., Ltd.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • Positron Corporation
  • Spectrum Pharmaceuticals, Inc.
  • Telix Pharmaceuticals Limited
Product Code: MRR-7A380DA7C46E

The SPECT & PET Radiopharmaceuticals Market was valued at USD 7.48 billion in 2025 and is projected to grow to USD 8.18 billion in 2026, with a CAGR of 10.28%, reaching USD 14.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.48 billion
Estimated Year [2026] USD 8.18 billion
Forecast Year [2032] USD 14.85 billion
CAGR (%) 10.28%

A concise foundational overview introducing SPECT and PET radiopharmaceuticals, their clinical roles, and strategic relevance to diagnostic and therapeutic pathways

This executive summary opens with a clear framing of SPECT and PET radiopharmaceuticals as indispensable tools within contemporary diagnostic and therapeutic pathways. The introduction situates these agents at the intersection of molecular biology, imaging physics, and clinical decision-making, highlighting their role in enabling precision diagnostics, treatment planning, and response assessment across cardiology, neurology, and oncology. It emphasizes how tracer chemistry and imaging modality together inform patient stratification and personalized care pathways, shaping clinical workflows from outpatient diagnostic centers to tertiary academic hospitals.

The section underscores the technological differentiation between PET and SPECT modalities and how radiochemistry choices influence diagnostic specificity, tracer availability, and operational workflows. It also outlines key stakeholders and value chain touchpoints, from isotope producers and radiopharmacies to imaging centers and regulatory authorities, while noting the operational dependencies that influence access and uptake. Finally, the introduction establishes the analytical perspective of this report: to synthesize scientific advancements, regulatory trends, supply chain considerations, and commercial strategies that will inform executive decision-making in the near term.

How emerging scientific breakthroughs, supply chain innovations, and regulatory evolution are reshaping the SPECT and PET radiopharmaceutical landscape across care settings

The landscape of SPECT and PET radiopharmaceuticals is being reshaped by a convergence of scientific, regulatory, and operational changes that collectively accelerate innovation and adoption. Advances in radiochemistry and cyclotron capabilities have broadened the palette of usable isotopes, enabling more disease-specific tracers that improve diagnostic sensitivity and provide actionable biological insights. Concurrently, improvements in detector technology and image reconstruction software have narrowed the performance gap between modalities in certain indications, prompting reassessment of clinical algorithms and investment priorities.

On the regulatory front, there is a discernible trend toward adaptive review pathways and greater regulatory dialogue around centralized versus decentralized production models. These developments are encouraging manufacturers and healthcare providers to experiment with new supply arrangements, including regional radiopharmacies and on-site synthesis, while simultaneously raising expectations for robust quality assurance and cold-chain management. In parallel, strategic collaborations among industry, academic centers, and contract development organizations are accelerating translational research and commercial-scale validation of next-generation tracers. Taken together, these shifts are creating a more dynamic environment in which innovation, supply resilience, and outcome-driven evidence increasingly determine commercial success.

Comprehensive assessment of how United States tariff adjustments implemented in 2025 affect sourcing, manufacturing, and global distribution of SPECT and PET radiopharmaceuticals

Tariff adjustments announced for the United States in 2025 have introduced new constraints and strategic considerations across the radiopharmaceutical value chain. Changes in import duties affect not only finished radiopharmaceutical products but also critical upstream inputs such as precursor chemicals, generator components, and specialized packaging materials. These adjustments have prompted procurement teams and manufacturers to reevaluate supplier selection, inventory policies, and cost-to-serve models to preserve operational continuity and maintain compliance with procurement and reimbursement frameworks.

In response, companies are increasingly exploring regionalization strategies that reduce exposure to cross-border tariff volatility. Such strategies include diversifying sourcing to alternative jurisdictions, increasing local or regional production capacity, and negotiating longer-term supplier agreements to stabilize input costs. These operational shifts have downstream implications for distribution timelines and inventory management, necessitating closer coordination among radiopharmacies, logistics providers, and imaging centers to ensure tracer availability aligns with clinical scheduling.

Regulatory and contract terms are also under scrutiny; procurement teams are updating contractual clauses to better allocate tariff-related risk and to secure price adjustments or supply guarantees. Meanwhile, health systems and providers are assessing whether changes in sourcing influence clinical operations or patient access, and they are engaging suppliers to develop contingency playbooks. Overall, the tariff-driven adjustments in 2025 have reinforced the strategic importance of supply chain flexibility, contractual clarity, and proactive stakeholder communication in preserving access to critical diagnostic agents.

Segment-focused intelligence revealing modality, radiopharmaceutical chemistries, clinical indications, end-user dynamics, and distribution channel implications for stakeholders

The sector's segmentation provides a pragmatic lens to translate scientific capability into operational and commercial choices. Based on Modality, the market is studied across PET and SPECT, a distinction that remains central because modality selection drives tracer chemistry preferences, equipment investments, and clinical pathway design. PET-centered workflows emphasize cyclotron or generator-linked isotopes and often demand tighter scheduling due to shorter half-lives, whereas SPECT workflows can leverage more widely available technetium-based kits and established distribution patterns.

Based on Radiopharmaceutical Type, the market is studied across Fluorine 18, Gallium 68, Indium 111, Iodine 123, and Technetium 99M. Within this framework, Fluorine 18 is further studied across FDG and Non FDG conjugates, reflecting the dual role of FDG as a longstanding oncology workhorse and the growing diversity of non-FDG tracers targeting specific molecular pathways. Technetium 99M is further studied across Cold Kits and Ready To Use formulations, recognizing that kit-based approaches support decentralized preparation while ready-to-use formats facilitate streamlined operations in high-throughput centers.

Based on Indication, the market is studied across Cardiology, Neurology, and Oncology, acknowledging that clinical utility, reimbursement pathways, and evidence requirements vary substantially by therapeutic area. Based on End User, the market is studied across Academic And Research Institutes, Diagnostic Centers, and Hospitals, which captures the operational and procurement heterogeneity between research-grade production environments and routine clinical service providers. Based on Distribution Channel, the market is studied across Direct Tender, Online Channels, and Third Party Logistics, reflecting how procurement and logistics choices influence availability, lead times, and compliance obligations. An integrated view across these segmentations clarifies where investment in tracer development, production capacity, or distribution infrastructure will yield the greatest clinical and commercial returns.

Regional dynamics decoded to understand Americas, Europe Middle East and Africa, and Asia-Pacific influences on technology adoption, supply resilience, and policy environments

Regional dynamics materially influence technology adoption, supply chain design, and regulatory approaches across the radiopharmaceutical landscape. In the Americas, ecosystems are characterized by a mix of advanced clinical adoption in major healthcare centers, growing private investment in radiochemistry infrastructure, and an evolving regulatory emphasis on balancing innovation with patient safety. These factors encourage development of complex PET tracers within established academic and commercial partnerships, while also prompting attention to logistical optimization for timely tracer delivery across large geographic spans.

Europe, Middle East & Africa present a heterogeneous landscape in which regulatory harmonization across blocks and national differences in reimbursement create both opportunities and friction points. Western European markets have mature adoption curves for novel tracers and supportive reimbursement mechanisms for evidence-backed indications, whereas other markets in the region are more price-sensitive and prioritize supply reliability. Middle Eastern centers of excellence are rapidly adopting advanced tracers, often through strategic partnerships, while African markets are beginning to address foundational infrastructure and workforce capacity to enable broader access.

Asia-Pacific is characterized by rapid capacity expansion, significant investments in cyclotron capabilities, and a strong appetite for innovative imaging agents that support oncology and neurology care pathways. Several markets in the region are building domestic radiopharmaceutical manufacturing capabilities to reduce dependency on imports, which in turn accelerates regional clinical trials and commercial rollouts. Across all regions, cross-border supply chain resilience, regulatory clarity, and local clinical evidence generation remain decisive factors shaping adoption trajectories.

Competitive and collaborative profiles of companies shaping radiopharmaceutical innovation, strategic partnerships, commercial scale-up, and value chain integration in nuclear medicine

Companies operating in the radiopharmaceutical segment are differentiated by their integrated capabilities across tracer discovery, isotope procurement, manufacturing scale-up, and distribution networks. Some organizations concentrate on advanced radiochemistry platforms and pipeline diversification, enabling rapid translation of novel ligands into clinical trials. Others focus on operational excellence in radiopharmacy and logistics, ensuring consistent on-time delivery of short-lived isotopes through robust cold-chain solutions and regional distribution hubs.

Strategic partnerships between technology developers, academic centers, and contract manufacturing organizations have become a common vehicle to bridge early-stage innovation and commercial supply. These collaborations mitigate development risk, leverage specialized manufacturing expertise, and expand access to specialized facilities necessary for regulatory submissions and clinical validation. At the same time, mergers, acquisitions, and licensing agreements are increasingly used to secure proprietary tracers or to consolidate supply chains, creating vertically integrated capabilities that can reduce time-to-market for selected indications.

Across the competitive landscape, differentiation is emerging through investments in tracer specificity, manufacturing agility, and evidence generation. Companies that align tracer development with clear clinical utility, scalable production pathways, and well-articulated pricing and reimbursement strategies are best positioned to translate scientific promise into clinical impact and commercial sustainability.

Actionable strategic recommendations for industry leaders to accelerate product development, secure resilient supply chains, and optimize clinical adoption pathways

Industry leaders should prioritize three complementary strategic actions to strengthen competitive positioning and ensure resilient access to radiopharmaceuticals. First, invest in flexible manufacturing and sourcing architectures that combine regional production capacity with validated alternative suppliers for critical precursors and packaging materials. This dual approach reduces exposure to single-source disruptions and tariff-driven cost volatility while enabling rapid scaling to meet clinical demand peaks.

Second, accelerate clinically focused evidence generation by aligning tracer development programs with clear clinical endpoints and real-world utility studies that demonstrate impact on diagnostic confidence, treatment selection, or patient outcomes. Embedding health economics analyses and payer engagement early in development will smooth adoption pathways and support reimbursement discussions. Third, foster strategic commercial partnerships that integrate manufacturing, distribution, and clinical adoption initiatives; these collaborations should include clear contractual provisions for risk-sharing around supply disruptions, quality compliance, and intellectual property management.

Additionally, leaders should invest in workforce development and digital infrastructure to optimize scheduling, inventory management, and regulatory documentation. By combining operational resilience with targeted clinical evidence and collaborative commercialization, organizations can accelerate adoption while managing cost and compliance pressures.

Rigorous research methodology explaining data sources, expert validation, analytical frameworks, and quality assurance protocols underpinning the insights presented

This research draws upon a mixed-methods approach that integrates qualitative expert interviews, primary stakeholder consultations, and a systematic review of peer-reviewed literature and regulatory guidance. Industry subject-matter experts, including clinical investigators, radiopharmacy managers, regulatory specialists, and supply chain leaders, were engaged to validate thematic findings and to surface operational realities that are not always visible in public documentation. The synthesis emphasizes triangulating perspectives to reduce bias and to ensure that recommendations reflect both scientific plausibility and commercial practicality.

Analytical frameworks applied in the study include value chain mapping, regulatory pathway comparison, and scenario analysis for supply chain resilience. Data quality assurance protocols encompassed source verification, cross-referencing of regulatory statements, and iterative validation with domain experts. Where appropriate, comparative case studies were used to illustrate how different production models and distribution strategies perform under varying operational and policy constraints. Throughout, emphasis was placed on transparency in assumptions, clear documentation of data sources, and rigorous peer review of analytical outputs to bolster confidence in the insights provided.

Concluding synthesis that distills strategic implications, persistent challenges, and opportunities for investment and clinical integration within the radiopharmaceutical sector

The closing synthesis distills the strategic implications for stakeholders across the radiopharmaceutical ecosystem, underscoring persistent challenges and actionable opportunities. Persistent challenges include supply chain fragility for short-lived isotopes, variability in regulatory and reimbursement environments across regions, and the need for stronger real-world evidence to support clinical adoption beyond early-adopter centers. Addressing these challenges will require concerted efforts in capacity building, regulatory dialogue, and targeted clinical validation that demonstrates meaningful patient benefit.

Opportunities exist in expanding tracer specificity for underserved indications, optimizing distribution models to balance centralization and decentralization, and leveraging digital tools to improve scheduling and resource allocation. Strategic investments in regional manufacturing capacity and evidence-generation partnerships can unlock broader clinical use while reducing exposure to geopolitical and tariff pressures. Ultimately, stakeholders that blend scientific rigor with operational adaptability and proactive payer engagement will be best positioned to translate radiopharmaceutical innovation into sustainable clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. SPECT & PET Radiopharmaceuticals Market, by Modality

  • 8.1. PET
  • 8.2. SPECT

9. SPECT & PET Radiopharmaceuticals Market, by Radiopharmaceutical Type

  • 9.1. Fluorine 18
    • 9.1.1. FDG
    • 9.1.2. Non FDG
  • 9.2. Gallium 68
  • 9.3. Indium 111
  • 9.4. Iodine 123
  • 9.5. Technetium 99M
    • 9.5.1. Cold Kits
    • 9.5.2. Ready To Use

10. SPECT & PET Radiopharmaceuticals Market, by Indication

  • 10.1. Cardiology
  • 10.2. Neurology
  • 10.3. Oncology

11. SPECT & PET Radiopharmaceuticals Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals

12. SPECT & PET Radiopharmaceuticals Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. SPECT & PET Radiopharmaceuticals Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. SPECT & PET Radiopharmaceuticals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. SPECT & PET Radiopharmaceuticals Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States SPECT & PET Radiopharmaceuticals Market

17. China SPECT & PET Radiopharmaceuticals Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced Accelerator Applications
  • 18.6. Bayer AG
  • 18.7. Bracco Imaging S.p.A.
  • 18.8. Cardinal Health, Inc.
  • 18.9. Curium Pharma
  • 18.10. Eckert & Ziegler
  • 18.11. GE Healthcare
  • 18.12. IBA Molecular
  • 18.13. Isotopia Molecular Imaging Ltd.
  • 18.14. Jubilant Pharma Limited
  • 18.15. Lantheus Holdings, Inc.
  • 18.16. Life Molecular Imaging GmbH
  • 18.17. Mallinckrodt plc
  • 18.18. Nihon Medi-Physics Co., Ltd.
  • 18.19. NorthStar Medical Radioisotopes, LLC
  • 18.20. Novartis AG
  • 18.21. Positron Corporation
  • 18.22. Spectrum Pharmaceuticals, Inc.
  • 18.23. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FDG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FDG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FDG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NON FDG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NON FDG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NON FDG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM 68, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM 68, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM 68, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDIUM 111, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDIUM 111, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDIUM 111, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE 123, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE 123, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE 123, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COLD KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COLD KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COLD KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY READY TO USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY READY TO USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY READY TO USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 144. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 145. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 166. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 168. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 169. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 176. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 177. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)